|
시장보고서
상품코드
2023558
줄기세포은행 시장 분석 및 예측(-2035년) : 유형, 서비스, 기술, 용도, 최종사용자Stem Cell Banking Market Analysis and Forecast to 2035: Type, Services, Technology, Application, End User |
||||||
세계의 줄기세포은행 시장은 2025년 53억 달러에서 2035년까지 96억 달러로 성장할 것으로 예상되며, CAGR은 5.9%에 달할 것으로 예측됩니다. 저장량은 전 세계적으로 확대되고 있으며, Be The Match와 같은 공공 및 민간 은행에 수백만 개의 샘플이 저장되어 있습니다. 요금에는 초기 처리 비용 1,000-2,500달러, 연간 보관 비용 100-300달러가 포함됩니다. 민간 은행은 일반적으로 공공 프로그램에 비해 높은 수수료를 책정하고 있습니다. 비용은 보관 기간, 처리 기술 및 제공되는 서비스에 따라 달라질 수 있습니다. 재생의료와 미래 치료용도에 대한 인식이 높아지면서 시료 보관의 확대와 장기적인 수익 창출을 주도하고 있습니다.
생명과학 분석 시장에서 AI의 '유형' 부문은 예측 분석이 주류를 이루고 있습니다. 이는 대규모 데이터세트를 통해 약물의 효과, 질병의 진행, 환자의 반응 등의 결과를 예측할 수 있기 때문입니다. 이 기능은 신약 개발 및 임상시험에서 의사결정을 개선하고 실패율과 비용을 절감하는 데 매우 중요합니다. 또한, 서술적 분석과 진단적 분석도 과거 데이터를 이해하고 패턴을 파악하기 위해 널리 활용되고 있습니다. 한편, 처방적 분석은 최적의 전략을 추천하는 방식으로 추진력을 얻고 있습니다. 데이터 기반 지식에 대한 수요 증가와 생물학적 데이터 생성량의 급증은 이 부문을 주도하는 주요 요인으로 작용하고 있습니다.
최종사용자 부문은 주로 제약회사 및 바이오테크 기업이 주도하고 있으며, AI 기반 분석을 활용하여 신약 개발 가속화, 임상시험 최적화 및 R&D 효율성 향상을 위해 활용하고 있습니다. 이들 조직은 개발 기간 단축과 성공률 향상을 위해 첨단 분석 기술에 많은 투자를 하고 있습니다. 연구기관도 중요한 역할을 하고 있으며, 유전체 연구와 생물의학 연구에 AI 도구를 활용하고 있습니다. 또한, CRO(Contract Research Organization)는 아웃소싱 트렌드와 비용 효율적이고 효율적인 연구 솔루션에 대한 니즈를 배경으로 전문적인 서비스를 제공하기 위해 AI 분석 도입을 확대하고 있습니다.
지역별 개요
북미는 선진화된 헬스케어 인프라, 재생의료에 대한 높은 인지도, 민간 줄기세포은행 시설의 강력한 존재감으로 줄기세포은행 시장에서 가장 큰 시장 점유율을 차지하고 있습니다. 미국은 잘 구축된 병원, 산부인과 센터, 바이오뱅킹 네트워크에 힘입어 제대혈 및 조직은행 서비스의 보급이 활발히 이루어지고 있어 지역 수요를 견인하고 있습니다. 특정 계층의 높은 가처분 소득과 양호한 보험 보급률은 가족들이 장기적인 줄기세포 보존에 투자하는 것을 더욱 촉진하고 있습니다. 또한, 강력한 규제 프레임워크, 재생의료 분야의 지속적인 연구 개발, 종양학 및 퇴행성 질환에 대한 임상 적용 확대는 북미의 세계 우위를 더욱 공고히 하고 있습니다.
아시아태평양은 출산율 증가, 헬스케어에 대한 인식 증가, 재생의료의 보급 확대로 인해 줄기세포은행 시장에서 가장 높은 CAGR을 기록할 것으로 예상됩니다. 중국, 인도, 일본, 한국 등의 국가에서는 민간 제대혈 은행 서비스가 빠르게 성장하고 있습니다. 중산층의 증가와 의료비 증가로 부모들은 줄기세포 보존을 통해 미래의 의료 보장을 위해 투자하고 있습니다. 또한, 만성질환 및 유전성 질환의 유병률 증가로 인해 첨단 치료 솔루션에 대한 수요가 증가하고 있습니다. 의료 인프라의 확충과 세계 기업 및 지역 바이오 뱅킹 기업 간의 협력 강화는 시장 성장을 더욱 가속화시키고 있습니다.
주요 동향 및 촉진요인
재생의료의 적용 확대와 줄기세포 치료에 대한 인식 제고
줄기세포은행 시장의 주요 시장 촉진요인은 재생의료에서 줄기세포의 적용 확대와 치료 가능성에 대한 인식이 높아지고 있다는 점입니다. 줄기세포는 혈액질환, 암, 면역질환, 퇴행성 질환의 치료에 널리 활용되고 있으며, 장기보존에 대한 수요를 견인하고 있습니다. 또한, 제대혈 은행의 의료적 이점에 대한 임산부들의 인식이 높아진 것도 제대혈 은행의 도입을 더욱 부추기고 있습니다. 줄기세포 연구의 지속적인 발전과 임상시험의 확대로 미래 치료 응용에 대한 신뢰가 높아지고 있습니다. 또한, 헬스케어 분야에 대한 투자 확대와 지원적인 연구 이니셔티브는 전 세계적으로 공공 및 민간 줄기세포은행 시설의 설립을 가속화하고 있습니다.
맞춤형 의료 및 재생의료 파이프라인 확장
줄기세포은행 시장의 주요 기회는 맞춤형 의료 및 재생의료 파이프라인의 확대에 있습니다. 줄기세포는 암, 신경질환, 심혈관질환 등 복잡한 질환에 대한 환자맞춤형 치료제 개발에 있어 매우 중요한 역할을 하고 있습니다. 조직공학 및 재생의료 분야의 임상연구개발이 증가함에 따라 보존된 줄기세포의 유용성이 크게 확대될 것으로 예상됩니다. 유전체 데이터와 통합된 바이오뱅킹 서비스의 성장은 정밀의료의 역량을 더욱 강화시키고 있습니다. 또한, 제약사, 연구기관 및 줄기세포은행 간의 협력은 새로운 상업화의 길을 열어주며, 세계 시장에서 장기적으로 큰 성장 기회를 가져다주고 있습니다.
목차
제1장 주요 요약
제2장 시장 하이라이트
제3장 시장 역학
제4장 부문 분석
제5장 지역별 분석
제6장 시장 전략
제7장 경쟁 정보
제8장 기업 개요
제9장 당사에 대해
KSM 26.05.18The global Stem Cell Banking Market is projected to grow from $5.3 billion in 2025 to $9.6 billion by 2035, at a compound annual growth rate (CAGR) of 5.9%. Storage volumes are expanding globally, with millions of samples preserved in public and private banks such as Be The Match. Pricing includes initial processing fees ranging from USD 1,000 to USD 2,500 and annual storage costs of USD 100 to USD 300. Private banks typically charge higher fees compared to public programs. Costs are influenced by storage duration, processing technology, and service offerings. Increasing awareness of regenerative medicine and future therapeutic applications is driving growth in sample storage and long-term revenue generation.
The Type segment in the AI in Life Science Analytics Market is dominated by predictive analytics, as it enables forecasting of outcomes such as drug efficacy, disease progression, and patient response using large datasets. This capability is critical for improving decision-making in drug development and clinical trials, helping reduce failure rates and costs. Descriptive and diagnostic analytics are also widely used for understanding historical data and identifying patterns, while prescriptive analytics is gaining momentum by recommending optimal strategies. The increasing need for data-driven insights and the surge in biological data generation are key factors driving this segment.
| Market Segmentation | |
|---|---|
| Type | Umbilical Cord Blood Stem Cells, Embryonic Stem Cells, Adult Stem Cells, Perinatal Stem Cells |
| Services | Collection and Transportation, Processing, Storage, Analysis |
| Technology | Cell Expansion, Cell Separation, Cryopreservation |
| Application | Regenerative Medicine, Drug Discovery and Development, Transplantation |
| End User | Hospitals, Research Institutes, Biotechnology Companies |
The End User segment is primarily led by pharmaceutical and biotechnology companies, which leverage AI-driven analytics to accelerate drug discovery, optimize clinical trials, and improve R&D efficiency. These organizations invest heavily in advanced analytics to reduce development timelines and enhance success rates. Research institutes also play a significant role, utilizing AI tools for genomic studies and biomedical research. Additionally, contract research organizations (CROs) are expanding their adoption of AI analytics to offer specialized services, driven by increasing outsourcing trends and the need for cost-effective and efficient research solutions.
Geographical Overview
North America holds the largest market share in the Stem Cell Banking Market due to its advanced healthcare infrastructure, high awareness of regenerative medicine, and strong presence of private stem cell banking facilities. The United States leads regional demand with widespread adoption of cord blood and tissue banking services, supported by well-established hospitals, maternity centers, and biobanking networks. High disposable income and favorable insurance penetration in certain segments further encourage families to invest in long-term stem cell storage. Additionally, strong regulatory frameworks, continuous R&D in regenerative therapies, and growing clinical applications in oncology and degenerative diseases reinforce North America's dominant position globally.
Asia Pacific is expected to register the highest CAGR in the Stem Cell Banking Market due to rising birth rates, increasing healthcare awareness, and expanding adoption of regenerative medicine. Countries such as China, India, Japan, and South Korea are witnessing rapid growth in private cord blood banking services. Growing middle-class populations and increasing healthcare spending are encouraging parents to invest in future medical security through stem cell preservation. Additionally, rising prevalence of chronic and genetic disorders is driving demand for advanced therapeutic solutions. Expanding healthcare infrastructure and increasing collaborations between global and regional biobanking companies further accelerate market growth.
Key Trends and Drivers
Rising applications of regenerative medicine and increasing awareness of stem cell therapies
A key driver of the Stem Cell Banking Market is the growing application of stem cells in regenerative medicine and increasing awareness of their therapeutic potential. Stem cells are widely used in treating blood disorders, cancers, immune diseases, and degenerative conditions, driving demand for long-term storage. Rising awareness among expectant parents about the medical benefits of cord blood banking is further boosting adoption. Continuous advancements in stem cell research and expanding clinical trials are increasing confidence in future therapeutic applications. Additionally, growing healthcare investments and supportive research initiatives are accelerating the establishment of both public and private stem cell banking facilities globally.
Expansion of personalized medicine and regenerative therapeutic pipelines
A major opportunity in the Stem Cell Banking Market lies in the expansion of personalized medicine and regenerative therapeutic pipelines. Stem cells play a crucial role in developing patient-specific treatments for complex diseases such as cancer, neurological disorders, and cardiovascular conditions. Increasing clinical research in tissue engineering and regenerative therapies is expected to significantly expand the utility of stored stem cells. Growth in biobanking services integrated with genomic data is further enhancing precision medicine capabilities. Additionally, collaborations between pharmaceutical companies, research institutes, and stem cell banks are creating new commercialization pathways, offering substantial long-term growth opportunities in the global market.
Research Scope
- Estimates and forecasts the overall market size across type, application, and region.
- Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
- Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
- Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
- Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
- Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
- Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.
Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.
TABLE OF CONTENTS
1 Executive Summary
- 1.1 Market Size and Forecast
- 1.2 Market Overview
- 1.3 Market Snapshot
- 1.4 Regional Snapshot
- 1.5 Strategic Recommendations
- 1.6 Analyst Notes
2 Market Highlights
- 2.1 Key Market Highlights by Type (Umbilical Cord Blood Stem Cells, Embryonic Stem Cells, Adult Stem Cells, Perinatal Stem Cells)
- 2.2 Key Market Highlights by Services (Collection and Transportation, Processing, Storage, Analysis)
- 2.3 Key Market Highlights by Technology (Cell Expansion, Cell Separation, Cryopreservation)
- 2.4 Key Market Highlights by Application (Regenerative Medicine, Drug Discovery and Development, Transplantation)
- 2.5 Key Market Highlights by End User (Hospitals, Research Institutes, Biotechnology Companies)
3 Market Dynamics
- 3.1 Macroeconomic Analysis
- 3.2 Market Trends
- 3.3 Market Drivers
- 3.4 Market Opportunities
- 3.5 Market Restraints
- 3.6 CAGR Growth Analysis
- 3.7 Impact Analysis
- 3.8 Emerging Markets
- 3.9 Technology Roadmap
- 3.10 Strategic Frameworks
- 3.10.1 PORTER's 5 Forces Model
- 3.10.2 ANSOFF Matrix
- 3.10.3 4P's Model
- 3.10.4 PESTEL Analysis
4 Segment Analysis
- 4.1 Market Size & Forecast by Type (2020-2035)
- 4.1.1 Umbilical Cord Blood Stem Cells
- 4.1.2 Embryonic Stem Cells
- 4.1.3 Adult Stem Cells
- 4.1.4 Perinatal Stem Cells
- 4.2 Market Size & Forecast by Services (2020-2035)
- 4.2.1 Collection and Transportation
- 4.2.2 Processing
- 4.2.3 Storage
- 4.2.4 Analysis
- 4.3 Market Size & Forecast by Technology (2020-2035)
- 4.3.1 Cell Expansion
- 4.3.2 Cell Separation
- 4.3.3 Cryopreservation
- 4.4 Market Size & Forecast by Application (2020-2035)
- 4.4.1 Regenerative Medicine
- 4.4.2 Drug Discovery and Development
- 4.4.3 Transplantation
- 4.5 Market Size & Forecast by End User (2020-2035)
- 4.5.1 Hospitals
- 4.5.2 Research Institutes
- 4.5.3 Biotechnology Companies
5 Regional Analysis
- 5.1 Global Market Overview
- 5.2 North America Market Size (2020-2035)
- 5.2.1 United States
- 5.2.1.1 Type
- 5.2.1.2 Services
- 5.2.1.3 Technology
- 5.2.1.4 Application
- 5.2.1.5 End User
- 5.2.2 Canada
- 5.2.2.1 Type
- 5.2.2.2 Services
- 5.2.2.3 Technology
- 5.2.2.4 Application
- 5.2.2.5 End User
- 5.2.3 Mexico
- 5.2.3.1 Type
- 5.2.3.2 Services
- 5.2.3.3 Technology
- 5.2.3.4 Application
- 5.2.3.5 End User
- 5.2.1 United States
- 5.3 Latin America Market Size (2020-2035)
- 5.3.1 Brazil
- 5.3.1.1 Type
- 5.3.1.2 Services
- 5.3.1.3 Technology
- 5.3.1.4 Application
- 5.3.1.5 End User
- 5.3.2 Argentina
- 5.3.2.1 Type
- 5.3.2.2 Services
- 5.3.2.3 Technology
- 5.3.2.4 Application
- 5.3.2.5 End User
- 5.3.3 Rest of Latin America
- 5.3.3.1 Type
- 5.3.3.2 Services
- 5.3.3.3 Technology
- 5.3.3.4 Application
- 5.3.3.5 End User
- 5.3.1 Brazil
- 5.4 Asia-Pacific Market Size (2020-2035)
- 5.4.1 China
- 5.4.1.1 Type
- 5.4.1.2 Services
- 5.4.1.3 Technology
- 5.4.1.4 Application
- 5.4.1.5 End User
- 5.4.2 India
- 5.4.2.1 Type
- 5.4.2.2 Services
- 5.4.2.3 Technology
- 5.4.2.4 Application
- 5.4.2.5 End User
- 5.4.3 South Korea
- 5.4.3.1 Type
- 5.4.3.2 Services
- 5.4.3.3 Technology
- 5.4.3.4 Application
- 5.4.3.5 End User
- 5.4.4 Japan
- 5.4.4.1 Type
- 5.4.4.2 Services
- 5.4.4.3 Technology
- 5.4.4.4 Application
- 5.4.4.5 End User
- 5.4.5 Australia
- 5.4.5.1 Type
- 5.4.5.2 Services
- 5.4.5.3 Technology
- 5.4.5.4 Application
- 5.4.5.5 End User
- 5.4.6 Taiwan
- 5.4.6.1 Type
- 5.4.6.2 Services
- 5.4.6.3 Technology
- 5.4.6.4 Application
- 5.4.6.5 End User
- 5.4.7 Rest of APAC
- 5.4.7.1 Type
- 5.4.7.2 Services
- 5.4.7.3 Technology
- 5.4.7.4 Application
- 5.4.7.5 End User
- 5.4.1 China
- 5.5 Europe Market Size (2020-2035)
- 5.5.1 Germany
- 5.5.1.1 Type
- 5.5.1.2 Services
- 5.5.1.3 Technology
- 5.5.1.4 Application
- 5.5.1.5 End User
- 5.5.2 France
- 5.5.2.1 Type
- 5.5.2.2 Services
- 5.5.2.3 Technology
- 5.5.2.4 Application
- 5.5.2.5 End User
- 5.5.3 United Kingdom
- 5.5.3.1 Type
- 5.5.3.2 Services
- 5.5.3.3 Technology
- 5.5.3.4 Application
- 5.5.3.5 End User
- 5.5.4 Spain
- 5.5.4.1 Type
- 5.5.4.2 Services
- 5.5.4.3 Technology
- 5.5.4.4 Application
- 5.5.4.5 End User
- 5.5.5 Italy
- 5.5.5.1 Type
- 5.5.5.2 Services
- 5.5.5.3 Technology
- 5.5.5.4 Application
- 5.5.5.5 End User
- 5.5.6 Rest of Europe
- 5.5.6.1 Type
- 5.5.6.2 Services
- 5.5.6.3 Technology
- 5.5.6.4 Application
- 5.5.6.5 End User
- 5.5.1 Germany
- 5.6 Middle East & Africa Market Size (2020-2035)
- 5.6.1 Saudi Arabia
- 5.6.1.1 Type
- 5.6.1.2 Services
- 5.6.1.3 Technology
- 5.6.1.4 Application
- 5.6.1.5 End User
- 5.6.2 United Arab Emirates
- 5.6.2.1 Type
- 5.6.2.2 Services
- 5.6.2.3 Technology
- 5.6.2.4 Application
- 5.6.2.5 End User
- 5.6.3 South Africa
- 5.6.3.1 Type
- 5.6.3.2 Services
- 5.6.3.3 Technology
- 5.6.3.4 Application
- 5.6.3.5 End User
- 5.6.4 Sub-Saharan Africa
- 5.6.4.1 Type
- 5.6.4.2 Services
- 5.6.4.3 Technology
- 5.6.4.4 Application
- 5.6.4.5 End User
- 5.6.5 Rest of MEA
- 5.6.5.1 Type
- 5.6.5.2 Services
- 5.6.5.3 Technology
- 5.6.5.4 Application
- 5.6.5.5 End User
- 5.6.1 Saudi Arabia
6 Market Strategy
- 6.1 Demand-Supply Gap Analysis
- 6.2 Trade & Logistics Constraints
- 6.3 Price-Cost-Margin Trends
- 6.4 Market Penetration
- 6.5 Consumer Analysis
- 6.6 Regulatory Snapshot
7 Competitive Intelligence
- 7.1 Market Positioning
- 7.2 Market Share
- 7.3 Competition Benchmarking
- 7.4 Top Company Strategies
8 Company Profiles
- 8.1 Cord Blood Registry
- 8.1.1 Overview
- 8.1.2 Product Summary
- 8.1.3 Financial Performance
- 8.1.4 SWOT Analysis
- 8.2 ViaCord
- 8.2.1 Overview
- 8.2.2 Product Summary
- 8.2.3 Financial Performance
- 8.2.4 SWOT Analysis
- 8.3 Cryo-Cell International
- 8.3.1 Overview
- 8.3.2 Product Summary
- 8.3.3 Financial Performance
- 8.3.4 SWOT Analysis
- 8.4 LifeCell International
- 8.4.1 Overview
- 8.4.2 Product Summary
- 8.4.3 Financial Performance
- 8.4.4 SWOT Analysis
- 8.5 China Cord Blood Corporation
- 8.5.1 Overview
- 8.5.2 Product Summary
- 8.5.3 Financial Performance
- 8.5.4 SWOT Analysis
- 8.6 StemCyte
- 8.6.1 Overview
- 8.6.2 Product Summary
- 8.6.3 Financial Performance
- 8.6.4 SWOT Analysis
- 8.7 Smart Cells International
- 8.7.1 Overview
- 8.7.2 Product Summary
- 8.7.3 Financial Performance
- 8.7.4 SWOT Analysis
- 8.8 Cryoviva
- 8.8.1 Overview
- 8.8.2 Product Summary
- 8.8.3 Financial Performance
- 8.8.4 SWOT Analysis
- 8.9 Future Health Biobank
- 8.9.1 Overview
- 8.9.2 Product Summary
- 8.9.3 Financial Performance
- 8.9.4 SWOT Analysis
- 8.10 Americord
- 8.10.1 Overview
- 8.10.2 Product Summary
- 8.10.3 Financial Performance
- 8.10.4 SWOT Analysis
- 8.11 Cells4Life
- 8.11.1 Overview
- 8.11.2 Product Summary
- 8.11.3 Financial Performance
- 8.11.4 SWOT Analysis
- 8.12 Biovault Family
- 8.12.1 Overview
- 8.12.2 Product Summary
- 8.12.3 Financial Performance
- 8.12.4 SWOT Analysis
- 8.13 Stemlife
- 8.13.1 Overview
- 8.13.2 Product Summary
- 8.13.3 Financial Performance
- 8.13.4 SWOT Analysis
- 8.14 CordVida
- 8.14.1 Overview
- 8.14.2 Product Summary
- 8.14.3 Financial Performance
- 8.14.4 SWOT Analysis
- 8.15 GeneCell International
- 8.15.1 Overview
- 8.15.2 Product Summary
- 8.15.3 Financial Performance
- 8.15.4 SWOT Analysis
- 8.16 Global Cord Blood Corporation
- 8.16.1 Overview
- 8.16.2 Product Summary
- 8.16.3 Financial Performance
- 8.16.4 SWOT Analysis
- 8.17 FamilyCord
- 8.17.1 Overview
- 8.17.2 Product Summary
- 8.17.3 Financial Performance
- 8.17.4 SWOT Analysis
- 8.18 Cell Care
- 8.18.1 Overview
- 8.18.2 Product Summary
- 8.18.3 Financial Performance
- 8.18.4 SWOT Analysis
- 8.19 Cryosave
- 8.19.1 Overview
- 8.19.2 Product Summary
- 8.19.3 Financial Performance
- 8.19.4 SWOT Analysis
- 8.20 BioEden
- 8.20.1 Overview
- 8.20.2 Product Summary
- 8.20.3 Financial Performance
- 8.20.4 SWOT Analysis
9 About Us
- 9.1 About Us
- 9.2 Research Methodology
- 9.3 Research Workflow
- 9.4 Consulting Services
- 9.5 Our Clients
- 9.6 Client Testimonials
- 9.7 Contact Us
